Avelumab ELISA Kit (ab237669)
Key features and details
- Sensitivity: 30 ng/ml
- Range: 100 ng/ml - 3000 ng/ml
- Sample type: Plasma, Serum
- Detection method: Colorimetric
- Assay type: Sandwich (quantitative)
- Reacts with: Human
Overview
-
Product name
Avelumab ELISA Kit
See all Avelumab kits -
Detection method
Colorimetric -
Precision
Intra-assay Sample n Mean SD CV% Overall < 15% Inter-assay Sample n Mean SD CV% Overall < 15% -
Sample type
Serum, Plasma -
Assay type
Sandwich (quantitative) -
Sensitivity
30 ng/ml -
Range
100 ng/ml - 3000 ng/ml -
Recovery
Sample specific recovery Sample type Average % Range Serum 85% - 115% -
Assay duration
Multiple steps standard assay -
Species reactivity
Reacts with: Human -
Product overview
Note: Avelumab ELISA kit ab237669 is intended for Research Use Only, not for use in diagnostic procedures.
This kit is a sandwich based ELISA kit. The color developed is proportional to the amount of Avelumab in the sample or standard. Results of samples can be determined directly using the standard curve.
-
Notes
This product is manufactured by BioVision, an Abcam company and was previously called E4556 BioSim™ Avelumab (Bavencio®)(Human) ELISA Kit. E4556-100 is the same size as the 96 test size of ab237669.
-
Platform
Microplate
Properties
-
Storage instructions
Store at +4°C. Please refer to protocols. -
Components 96 tests 96 tests Assay Buffer 2 x 50ml 2 x 50ml Avelumab Standard S1 1 x 0.3ml 1 x 0.3ml Avelumab Standard S2 1 x 0.3ml 1 x 0.3ml Avelumab Standard S3 1 x 0.3ml 1 x 0.3ml Avelumab Standard S4 1 x 0.3ml 1 x 0.3ml Avelumab Standard S5 1 x 0.3ml 1 x 0.3ml Avelumab Standard S6 1 x 0.3ml 1 x 0.3ml Avelumab Standard S7 1 x 0.3ml 1 x 0.3ml HRP-conjugate Probe 1 x 12ml 1 x 12ml Micro ELISA Plate 1 unit 1 unit Plate sealers 2 units 2 units Stop Solution 1 x 12ml 1 x 12ml TMB substrate 1 x 12ml 1 x 12ml Wash buffer (20X) 1 x 50ml 1 x 50ml -
Relevance
Avelumab (Bavencio®) is a fully human anti-PD-L1 IgG1 lambda monoclonal antibody that has a molecular weight of approximately 147 kDa. Avelumab binds PD-L1 and blocks the interaction between PD-L1 and its receptors PD-1 and B7-1. By inhibiting PD-L1 interactions, avelumab is thought to enable the activation of T-cells and the adaptive immune system. By retaining anative Fc-region, avelumab is thought to engage the innate immune system and may induce antibody-dependent cell-mediated cytotoxicity. Importantly, avelumab has not shown antibody-dependent cell mediated cytotoxicity against immune cell subsets in humans. -
Alternative names
- Bavencio
Images
Datasheets and documents
-
SDS download
-
Datasheet download
References (1)
ab237669 has been referenced in 1 publication.
- Kanemaru H et al. Single administration of avelumab induced a complete response in thyroid transcription factor 1-positive combined Merkel cell carcinoma. J Dermatol 47:1317-1321 (2020). PubMed: 32794263